Claims

1. A crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

2. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 9.8°, 9.9°, 11.7°, 17.8°, 18.6°, 20.0°, 21.5°, 22.8°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

3. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to claim 1, which essentially shows the X-ray powder diffraction pattern as depicted in Figure 1.

4. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, according to any one of claims 1 to 3, for use in the manufacture of a pharmaceutical composition, wherein said pharmaceutical composition comprises as active ingredient the compound {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and at least one therapeutically inert excipient.

5. A pharmaceutical composition comprising as active ingredient the crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to any one of claims 1 to 3, and at least one therapeutically inert excipient.

6. The pharmaceutical composition according to claim 5, which comprises as therapeutically inert excipient microcrystalline cellulose, lactose, hydroxypropylcellulose, croscarmellose sodium and magnesium stearate.

7. The pharmaceutical composition according to claim 6, wherein said pharmaceutical composition is a solid pharmaceutical composition comprising

- the crystalline form of the compound {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to any one of claims 1 to 3 in a total amount from 5 to 25% in weight based on the total weight of the pharmaceutical composition,
- microcrystalline cellulose in a total amount from 20 to 30% in weight based on the total weight of the pharmaceutical composition,
- lactose in a total amount from 40 to 65% in weight based on the total weight of the pharmaceutical composition, hydroxypropylcellulose in a total amount from 1 to 3% in weight based on the total weight of the pharmaceutical composition,
- croscarmellose sodium in a total amount from 2 to 8% in weight based on the total weight of the pharmaceutical composition, and
- magnesium stearate in a total amount from 0.2 to 2% in weight based on the total weight of the pharmaceutical composition;

wherein the total percent in weight of the solid pharmaceutical composition is 100.

8. The solid pharmaceutical composition according to claim 7, wherein said pharmaceutical composition is in form of a tablet.